UNSPSC 51171985: Vestronidase alfa

Vestronidase alfa is a therapy intended to replace the deficient lysosomal enzyme beta-glucuronidase to help break down the glycosaminoglycans that accumulate in the tissues of patients with MPS 7.

UNSPSC 51171985 Vestronidase alfa, a Commodity code, encompasses prescription pharmaceuticals and biologic agents procured by state and local health agencies, particularly public health departments and government employee benefit programs serving specialized patient populations including HIV/AIDS patients, emergency medical services, and opioid-use disorder treatment. Recent state and local solicitations under this code show pharmacy dispensing services, emergency medication distribution, and pharmacy benefit management as the primary acquisition vehicles, with procurement bodies including county health departments, municipal fire departments, state health commissions, and county employee benefits programs.

DeKalb Public Health in Georgia has posted two rebid RFQs for primary care medication dispensing services supporting Ryan White patients (most recent July 15, 2026, due July 27, 2026), and the Illinois Chief Procurement Office extended a six-month master contract through Emergent Devices Inc. for Narcan 4mg Nasal Spray at approximately $1.1 million monthly statewide (June 2026). The City of Tucson Fire Department's June 2026 RFP for BLS/ALS pharmaceuticals and supplies with vending machine services, funded through ARPA, HUD, and FTA grants, demonstrates broader emergency-response procurement under this family. Geographic activity spans Georgia (DeKalb Public Health), Illinois (statewide cooperative purchasing through MMCAP and CPO-GS), Florida (Seminole County naloxone procurement and Pinellas County PBM services RFP), Arizona (Tucson Fire), and multistate cooperative agreements including MMCAP (Minnesota-administered, serving Oregon and other participants). The code shows consistent activity from county and municipal health and emergency services buyers, with fee-for-service reimbursement and competitive sealed bidding as standard acquisition methods; however, the source material does not specifically confirm that vestronidase alfa itself appears in recent procurement records—most opportunities reference broader pharmaceutical categories or specific off-the-shelf medications (naloxone, primary care generics) rather than this biopharmaceutical by name.